Table 1. Patients characteristics.
| Characteristic | No. of patients (%) (n=4,033) |
|---|---|
| Age (yr) | |
| ≤50 | 2,436 (60.4) |
| >50 | 1,592 (39.5) |
| Unknown | 5 (0.1) |
| T stage | |
| T1 | 2,163 (53.6) |
| T2 | 1,870 (46.4) |
| Histologic grade | |
| I | 198 (4.9) |
| II | 964 (23.9) |
| III | 2,300 (57.0) |
| Unknown | 571 (14.2) |
| Histology | |
| IDC | 3,992 (99.0) |
| ILC | 41 (1.0) |
| LVI | |
| No | 2,641 (65.5) |
| Yes | 591 (14.7) |
| Unknown | 801 (19.9) |
| Operation | |
| Mastectomy | 1,674 (41.5) |
| BCS | 2,332 (57.8) |
| Unknown | 27 (0.7) |
| Radiotherapy | |
| None | 1,640 (40.7) |
| Done | 2,197 (54.5) |
| Unknown | 196 (4.9) |
| Chemotherapy regimen | |
| None | 549 (13.6) |
| AC | 1,419 (35.2) |
| FAC | 875 (21.7) |
| CMF | 1,190 (29.5) |
IDC=invasive ductal carcinoma; ILC=invasive lobular carcinoma; LVI=lymphovascular invasion; BCS=breast-conserving surgery; AC=anthracyclin and cyclophosphamide; FAC=5-fluorouracil, anthracyclin, and cyclophosphamide; CMF=cyclophosphamide, methotrexate, and 5-fluorouracil.